Evidence map›Paper›PMID 38256599›Full record

ArticleJournal of clinical medicine2024

Glucose Metabolism and Cognitive Decline in Progressive Supranuclear Palsy and Corticobasal Syndrome: A Preliminary Study.

Natalia Madetko-Alster, Dagmara Otto-Ślusarczyk, Marta Struga, Michał Kutyłowski, Agnieszka Drzewińska, Karolina Duszyńska-Wąs, Bartosz Migda, Piotr Alster

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Natalia Madetko-AlsterDepartment of Neurology, Medical University of Warsaw, Kondratowicza 8, 03-242 Warsaw, Poland.ORCID 0000-0001-8685-475X
Dagmara Otto-ŚlusarczykDepartment of Biochemistry, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland.
Marta StrugaDepartment of Biochemistry, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland.ORCID 0000-0002-0181-3607
Michał KutyłowskiDepartment of Radiology, Mazovian Brodno Hospital, Kondratowicza 8, 03-242 Warsaw, Poland.ORCID 0000-0003-2202-9237
Agnieszka DrzewińskaDepartment of Neurology, Mazovian Brodno Hospital, Kondratowicza 8, 03-242 Warsaw, Poland.
Karolina Duszyńska-WąsDepartment of Neurology, Mazovian Brodno Hospital, Kondratowicza 8, 03-242 Warsaw, Poland.
Bartosz MigdaDiagnostic Ultrasound Lab, Department of Pediatric Radiology, Medical University of Warsaw, 02-091 Warsaw, Poland.
Piotr AlsterDepartment of Neurology, Medical University of Warsaw, Kondratowicza 8, 03-242 Warsaw, Poland.ORCID 0000-0002-5371-6817
Medical University of Warsaw · PL

Funding

Medical University of Warsaw M/MB/N/22
6 · The paper itself

Abstract

Multiple studies have analyzed the possible correlations between diabetes and Alzheimer's disease. Less is known about the context of cognitive deterioration among patients with atypical Parkinsonian syndromes and glucose metabolism impairment. The aim of this study was to evaluate the association between the impaired glucose metabolism and cognitive decline among patients with progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). The study included 22 patients with PSP and CBS with disease durations varying from 3 to 6 years. The levels of glycated hemoglobin (HbA1C), fasting blood glucose, fasting C-peptide and the presence of microalbuminuria were evaluated, and oral glucose tolerance tests (OGTT) were performed. Based on the OGTT results, the glycemic variability, mean glycemia, glycemia standard deviation (SD) and coefficient of variation (%CV) were calculated. All patients underwent a three-Tesla brain magnetic resonance (MRI) examination and neuropsychological cognitive assessment with the use of standardized scales: Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE) and Frontal Assessment Battery (FAB). A statistical analysis revealed that poor control of glycemia with high glycemic variability and increased atrophy of the medial temporal lobe among patients with PSP and CBS correlated with worse cognitive performance independent of age or sex, even among patients who did not fulfill the criteria for diabetes. The study results indicate the importance of glucose metabolism control and optimal treatment in the context of cognition maintenance among patients with PSP and CBS. Due to the relatively small number of analyzed patients, the issue requires further assessment. To the best of our knowledge, this is the first study discussing the role of glycemic variability in atypical Parkinsonian syndromes.

Indexed as

atypical Parkinsonian syndromecognitive impairmentcorticobasal syndromeglycemic variabilityimpaired glucose metabolismprogressive supranuclear palsy

Identifiers

PMID38256599
PMCPMC10816752
OpenAlexW4390878365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.